CY1120610T1 - NEW COMPOSITION FOR THE EXTRAORDINARY REDUCTION OF BETA-AMYLOIDS AND ITS PRODUCTION PROCESS - Google Patents

NEW COMPOSITION FOR THE EXTRAORDINARY REDUCTION OF BETA-AMYLOIDS AND ITS PRODUCTION PROCESS

Info

Publication number
CY1120610T1
CY1120610T1 CY181100895T CY181100895T CY1120610T1 CY 1120610 T1 CY1120610 T1 CY 1120610T1 CY 181100895 T CY181100895 T CY 181100895T CY 181100895 T CY181100895 T CY 181100895T CY 1120610 T1 CY1120610 T1 CY 1120610T1
Authority
CY
Cyprus
Prior art keywords
beta
amyloids
subject
dialysis
composition
Prior art date
Application number
CY181100895T
Other languages
Greek (el)
Inventor
Rogelio B Santos Jr
Stanley Stein
Chinnaswamy Kasinathan
Original Assignee
Amylex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/PH2013/000005 external-priority patent/WO2013162387A1/en
Application filed by Amylex Pharmaceuticals Inc filed Critical Amylex Pharmaceuticals Inc
Publication of CY1120610T1 publication Critical patent/CY1120610T1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει μια ασφαλή, αξιόπιστη και οικονομική διαδικασία για την παρασκευή ενός βελτιωμένου παρασκευάσματος υγρού διαπίδυσης, το οποίο είναι αποτελεσματικό για εξωσωματική αγωγή, μέσω μιας μεθόδου διήθησης αίματος, μιας πάθησης που συνδέεται με Βήτα-Αμυλοειδές σε ένα υποκείμενο, η οποία μέθοδος περιλαμβάνει την παρασκευή μιας σύνθεσης που περιλαμβάνει ένα πεπτίδιο KLVFF ή μια παραλλαγή αυτού ως παράγοντα σύλληψης και πρόσδεσης και έναν φορέα, και την ανάμειξη της εν λόγω σύνθεσης με ένα διάλυμα αιμοκάθαρσης. Η μέθοδος χρησιμοποιεί ένα μικρό, φθηνό και απλό πρότυπο μηχάνημα αιμοκάθαρσης που απομακρύνει εξωσωματικά τα Β-αμυλοειδή χωρίς να επιτρέπει στο βήτα-αμυλοειδές να επιστρέψει στο σώμα ενός υποκειμένου και χωρίς να χρειάζεται να εκτιμήσει λεπτομερώς την απόδοση και τα χαρακτηριστικά μιας μεμβράνης αιμοκάθαρσης και χωρίς να τίθεται σε κίνδυνο η κατάσταση της υγείας του υποκειμένου.The present invention provides a safe, reliable and economical process for preparing an improved dialysis fluid preparation, which is effective for in vitro treatment, by a blood filtration method, a Beta-Amyloid-associated condition in a subject, which method comprises preparing a composition comprising a KLVFF peptide or a variant thereof as a capture and binding agent and a carrier, and mixing said composition with a dialysis solution. The method uses a small, inexpensive and simple standard dialysis machine that removes B-amyloids extracorporeally without allowing beta-amyloid to return to a subject's body without having to evaluate in detail the performance and characteristics of a dialysis membrane and without the state of health of the subject is endangered.

CY181100895T 2012-04-26 2018-08-28 NEW COMPOSITION FOR THE EXTRAORDINARY REDUCTION OF BETA-AMYLOIDS AND ITS PRODUCTION PROCESS CY1120610T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261638672P 2012-04-26 2012-04-26
PCT/PH2013/000005 WO2013162387A1 (en) 2012-04-26 2013-01-30 Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof
PH12013000037 2013-01-30

Publications (1)

Publication Number Publication Date
CY1120610T1 true CY1120610T1 (en) 2019-12-11

Family

ID=68771305

Family Applications (1)

Application Number Title Priority Date Filing Date
CY181100895T CY1120610T1 (en) 2012-04-26 2018-08-28 NEW COMPOSITION FOR THE EXTRAORDINARY REDUCTION OF BETA-AMYLOIDS AND ITS PRODUCTION PROCESS

Country Status (1)

Country Link
CY (1) CY1120610T1 (en)

Similar Documents

Publication Publication Date Title
EA201990043A1 (en) ANTIBACTERIAL CONNECTIONS
PH12015501558A1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
EA201790377A1 (en) ANTIBODIES TO GLUCAGON AND THEIR APPLICATIONS
EA201890204A1 (en) ANTIBACTERIAL CONNECTIONS
EA201591427A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
BR112016015140A2 (en) tandem-fab immunoglobulin and its uses
EA201590343A1 (en) ALKYLPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES
UA118332C2 (en) Cs27l antigen binding proteins
EA201590667A1 (en) ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
EA201591166A1 (en) AUTOTAXIN INHIBITORS
EA201691060A1 (en) TRANSTIRETINAL (TTR) AMYLOIDOSIS THERAPY WITH ANTIBODIES AND ALSO ANTIBODIES RECEIVED FROM HUMAN FOR THE INDICATED THERAPY
EA201992133A1 (en) PIPERIDINO-PYRIMIDINE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS
EA202193044A2 (en) METHODS OF TREATMENT OF TAUPATHY
EA201591430A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
EA201590890A1 (en) DERIVATIVES 5-FLUOR-N- (PYRIDIN-2-IL) PYRIDIN-2-AMINE CONTAINING A SULPHOXIMINE GROUP
EA201591426A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
EA201270018A1 (en) Opsync ligands, compositions and methods of use
BR112013010857A2 (en) double domain variable imonoglubulines and their uses
BR112012032778A2 (en) "multispecific and multivalent proteins"
EA201591432A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR MODULATION OF HEMOGLOBIN
EA201500383A1 (en) DERIVATIVES 1,2,4-TRIAZINE FOR THE TREATMENT OF VIRAL INFECTIONS
EA201492040A1 (en) BICYCLICALLY SUBSTITUTED URACILES AND THEIR APPLICATION
EA201992707A1 (en) COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
TR201909447T4 (en) Aramkol salts.
EA201692279A1 (en) METHOD FOR REDUCING IMMUNOGENIC PROTEIN AND PEPTIDE